FDA Approves Oral Drug That Doubles Pancreatic Cancer Survival

The U.S. Food and Drug Administration on Wednesday approved Rasonque, a first-of-its-kind oral medication for advanced pancreatic cancer, marking a significant breakthrough in treating one of the deadliest forms of the disease. The once-daily pill, developed by Revolution Medicines and known generically as daraxonrasib, is designed to block multiple forms of the RAS protein, a mutation that drives tumor growth in more than 90% of pancreatic cancers. The approval was based on results from a Phase 3 clinical trial involving 500 adults with previously treated metastatic pancreatic adenocarcinoma. Patients who received Rasonque lived for a median of 13.2 months, nearly doubling the 6.